Title (en)

CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS.

Title (de)

CYCLOALKYL SUBSTITUIERTE GLUTARAMIDE ALS ANTIHYPERTENSIVE WIRKSTOFFE.

Title (fr)

AGENTS ANTIHYPERTENSIFS AU GLUTARAMIDE SUBSTITUE PAR CYCLOALKYLE.

Publication

EP 0594588 A1 19940504 (EN)

Application

EP 91903839 A 19910214

Priority

- EP 9100296 W 19910214
- GB 9004260 A 19900226

Abstract (en)

[origin: WO9113054A1] Compounds of formula (I), wherein A completes a 5 or 6 membered carbocyclic ring which may be saturated or monounsaturated; Y is an alkylene group of from 1 to 9 carbon atoms; R<1> is H or (C1-C4)alkyl; R and R<4> are H, (C1-C6)alkyl, (C3-C7)cycloalkyl, benzyl, or an alternative biolabile ester-forming group; R<2> is defined to include a range of substituent groups including (C1-C6)alkoxy, (C1-C4)alkoxy-(C1-C6)alkoxy and various substituted-alkyl, amino, substituted amino, aryl and heterocyclyl substituents linked directly or by O, S(O)n, NR<6>, CO or CONR<6> wherein R<6> is H, (C1-C4)alkyl or aryl(C1-C4)alkyl and n is 0, 1 or 2; R<3> is a group of formula (II), wherein R<13> is H, halo, 4-OH, 4-(C1-C6 alkoxy), 4-(C3-C7 cycloalkoxy), 4-(C2-C6 alkenyloxy), 4-[(C1-C6 alkoxy)carbonyloxy], 4-[(C3-C7 cycloalkyloxy)carbonyloxy], or 3-(C1-C4 alkyl)SO2NH-; and R<14> is H, (C1-C4)alkyl, (C1-C4)alkoxy, (C2-C6)alkanoyl or halo; or R<3> is a group of formulae (III) or (IV), wherein said groups may optionally be substituted in the fused benzene ring by (C1-C4)alkyl, (C1-C4)alkoxy, OH, halo or CF3; or are atriopeptidase inhibitors or utility in the treatment of hypertension and heart failure.

Abstract (fr)

On décrit des composés de formule (I), où A complète un anneau carbocyclique à 5 ou 6 branches qui peut être saturé ou mono non saturé; Y est un groupe alkylène ayant entre 1 et 9 atomes de carbone; R1 est H ou (C1-C4)alkyle; R et R4 sont H, (C1-C6)alkyle, (C3-C7)cycloalkyle, benzyle, ou un autre groupe biolabile formant des esters; R2 est défini pour inclure une série de groupes substituants comprenant (C1-C6)alkoxy, (C1-C4)alkoxy-(C1-C6)alkoxy et divers substituants à substitution d'alkyle, amino, à substitution d'amino, aryle et hétérocyclyle liés directement ou par O, S(O)n, NR6, CO ou CONR6, où R6 est H, (C1-C4)alkyle ou aryle(C1-C4)alkyle et n est 0, 1 ou 2; R3 est un groupe de la formule (II), où R13 est H, halo, 4-OH, 4-(C1-C6alkoxy), 4-(C3-C7 cycloalkoxy), 4-(C2>-C6 alkényloxy), 4-[(C1-C6alkoxy)carbonyloxy], 4-[(C3-C7 cycloalkyloxy)carbonyloxy], ou 3-(C1-C4 alkyl)SO2NH-; et R14 est H, (C1-C4)alkyle, (C1-C4alkoxy, (C2-C6alkanoyle ou halo; ou R3 est un groupe de formule (III) où lesdits groupes peuvent être substitués facultativement dans l'anneau de benzène fusionné par (C1-C4)alkyle, (C1-C4)alkoxy, OH, halo ou CF3; ou ils sont des inhibiteurs d'atriopeptidase utiles dans le traitement de l'hypertension et d'insuffisance cardiaque.

IPC 1-7

C07C 237/24

IPC 8 full level

A61K 31/195 (2006.01); **A61K 31/215** (2006.01); **A61K 31/35** (2006.01); **A61K 31/351** (2006.01); **A61K 31/40** (2006.01); **A61K 31/403** (2006.01); **A61K 31/404** (2006.01); **A61K 31/415** (2006.01); **A61K 31/445** (2006.01); **A61P 9/04** (2006.01); **A61P 9/12** (2006.01); **A61P 43/00** (2006.01); **C07C 233/63** (2006.01); **C07C 235/40** (2006.01); **C07C 237/22** (2006.01); **C07C 237/24** (2006.01); **C07C 237/36** (2006.01); **C07C 237/42** (2006.01); **C07C 247/12** (2006.01); **C07C 271/22** (2006.01); **C07C 271/66** (2006.01); **C07C 273/18** (2006.01); **C07C 311/06** (2006.01); **C07C 317/44** (2006.01); **C07C 317/48** (2006.01); **C07C 323/52** (2006.01); **C07C 323/60** (2006.01); **C07D 209/14** (2006.01); **C07D 211/46** (2006.01); **C07D 211/58** (2006.01); **C07D 211/74** (2006.01); **C07D 231/56** (2006.01); **C07D 233/60** (2006.01); **C07D 295/14** (2006.01); **C07D 295/145** (2006.01); **C07D 309/12** (2006.01); **C07D 521/00** (2006.01); C07C 275/22 (2006.01)

CPC (source: EP)

A61P 9/04 (2017.12); **A61P 9/12** (2017.12); **A61P 43/00** (2017.12); **C07C 233/63** (2013.01); **C07C 235/40** (2013.01); **C07C 237/24** (2013.01); **C07C 237/36** (2013.01); **C07C 247/12** (2013.01); **C07C 271/22** (2013.01); **C07C 271/66** (2013.01); **C07C 273/1854** (2013.01); **C07C 317/44** (2013.01); **C07C 317/48** (2013.01); **C07C 323/60** (2013.01); **C07D 211/46** (2013.01); **C07D 211/58** (2013.01); **C07D 211/74** (2013.01); **C07D 231/12** (2013.01); **C07D 233/56** (2013.01); **C07D 249/08** (2013.01); **C07D 295/145** (2013.01); **C07D 309/12** (2013.01); C07C 2601/08 (2017.04)

Citation (search report)

See references of WO 9113054A1

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IT LI LU NL SE

DOCDB simple family (publication)

WO 9113054 A1 19910905; CA 2073450 A1 19910827; EP 0594588 A1 19940504; FI 923780 A0 19920821; FI 923780 A 19920821; GB 9004260 D0 19900418; IE 910615 A1 19910828; JP H05504146 A 19930701; PT 96863 A 19911129

DOCDB simple family (application)

EP 9100296 W 19910214; CA 2073450 A 19910214; EP 91903839 A 19910214; FI 923780 A 19920821; GB 9004260 A 19900226; IE 61591 A 19910225; JP 50397391 A 19910214; PT 9686391 A 19910225